Manifestación contra la reforma judicial promovida por Berlusconi

ROMA (AFP) – Decenas de miles de personas -200.000, según los organizadores- se congregaron este sábado en la capital de Italia para manifestarse contra dos proyectos de ley que según ellos están hechos a medida del jefe del gobierno Silvio Berlusconi, constató la AFP.

The industrialend-user segment is also emerging as a significant source of retrofits, as plantowners have been investing in capacity expansions, new expansions, andrefurbishing aging power generation plants to improve productivity. Industrieshad invested substantially in brown field projects and maintenance and capacityreplacement in 2007, providing relief to gasket manufacturers. Although the economic slump is likely to defer a few industrial projects thatwere to be taken up in 2009 and 2010, the already initiated ones will go a longway in shoring up the gaskets market. The postponement of oil and gas expansionprojects will also curb the rapid growth of the market until 2010. “Decreasingoil prices are expected to reduce capacities until 2010, but with marketstabilization, the refurbishment of existing plants becomes necessary,” says theanalyst of this research. “The aftermarket business will see the gaskets marketsgrow moderately during this period.” Acknowledging the challenge of operating inthese difficult economic environments, companies all over the world are strivingto lower operational expenditure and improve returns on investment. With manycompanies also looking to considerably downsize maintenance personnel forequipment repair or breakdown, there is a large market for products that offerbetter reliability and life cycle cost benefits.

DUBLIN–(Business Wire)–Research and Markets( http://) hasannounced the addition of the “Three Case Studies in Technology Innovation(Apple, Google, Pixar)” report to their offering. This bundled report contains three innovation case studies, and focus on theinnovation efforts of Apple, Google, and Pixar. These three companies haveconsistently defined the cutting-edge in technology. In the Apple case study, learn how the company has re-emerged as one of theworld’s most innovative companies. Apple has managed to sustain its innovationefforts with calculated, consistent increases in R&D spending and rapid-firelaunches of new products and upgrades.

SÍDNEY (AFP) – La tenista belga Justine Henin, que la semana que viene volverá a la competición en el torneo de Brisbane tras haber estado retirada durante dos años, aseguró este martes que tiene un mejor juego y que su experiencia podría ayudarle a ganar el Abierto de Australia.

(NASDAQ:AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrinetherapy and oncology, announced today that it has received commitments topurchase US$10 million of units comprised of common shares and common sharepurchase warrants in a registered direct offering. AEterna Zentaris expects toreceive net proceeds of approximately US$9.25 million after deductingplacement agent fees and other offering expenses. Under the terms of aSecurities Purchase Agreement, the Company will sell to such institutionalinvestors an aggregate of 5,319,149 common shares of its capital at a price ofUS$1.88 per share and issue warrants to acquire an aggregate of 1,861,702common shares at an exercise price of US$2.06 per share.The warrants to purchase additional common shares of AEterna Zentaris will beexercisable beginning three months after issuance and will expire 30 monthsafter issuance. All of the common shares and warrants were offered pursuant toan effective shelf registration statement.

Proceeds from the transaction willbe used for general corporate purposes, including clinical development of ourleading oncology and endocrinology compounds. The offering is expected to beconsummated no later than June 24, 2009, subject to customary closingconditions.Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc.,(Nasdaq: RODM ( )), acted as the exclusiveplacement agent for the transaction. The placement agent will receivethirty-month warrants, exercisable beginning six months after issuance, topurchase 287,234 common shares at US$2.35 per share.In connection with the offering, the Company will file a prospectus supplementto its existing base shelf prospectus with the Canadian securities regulatoryauthorities and with the Securities and Exchange Commission. Copies of theprospectus supplement and accompanying prospectus may be obtained directlyfrom the Company or by contacting AEterna Zentaris Inc., 1405 duParc-Technologique Boulevard, Quebec City, Canada G1P 4P5.This press release shall not constitute an offer to sell or a solicitation ofan offer to buy any securities nor shall there be any sale of such securitiesin any jurisdiction in which such offer, solicitation or sale would beunlawful prior to registration or qualification under the securities laws ofany such jurisdiction.

This offering is being made by means of a prospectussupplement to the Company’s existing base prospectus that is part of its shelfregistration statement previously filed with and declared effective by theSecurities and Exchange Commission.About AEterna Zentaris Inc.AEterna Zentaris Inc. is a global biopharmaceutical company focused onendocrine therapy and oncology, with proven expertise in drug discovery,development and commercialization. News releases and additional informationare available at StatementsThis press release contains forward-looking statements made pursuant to thesafe harbor provisions of the U.S. Securities Litigation Reform Act of 1995.Forward-looking statements involve known and unknown risks and uncertainties,which could cause the Company’s actual results to differ materially from thosein the forward-looking statements. Such risks and uncertainties include, amongothers, the availability of funds and resources to pursue R&D projects, thesuccessful and timely completion of clinical studies, the ability of theCompany to take advantage of business opportunities in the pharmaceuticalindustry, uncertainties related to the regulatory process and general changesin economic conditions. Investors should consult the Company’s quarterly andannual filings with the Canadian and U.S.

securities commissions foradditional information on risks and uncertainties relating to theforward-looking statements. Investors are cautioned not to rely on theseforward-looking statements. The Company does not undertake to update theseforward-looking statements. We disclaim any obligation to update any suchfactors or to publicly announce the result of any revisions to any of theforward-looking statements contained herein to reflect future results, eventsor developments except if we are requested by a governmental authority orapplicable law.SOURCEAETERNA ZENTARIS INC.Investor Relations: Ginette Vallieres, Investor Relations Coordinator, (418)652-8525 ext. 265, ; Media Relations: Paul Burroughs,Director of Communications, (418) 652-8525 ext. 406, .

MADRID (AFP) – El índice Ibex-35 de los principales valores de la Golsa de Madrid perdió este lunes 1,09% (124,10 puntos) hasta situarse en los 11.249,30 puntos al final de una sesión marcada por la caída de los títulos bancarios.

(NASDAQ:AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrinetherapy and oncology, announced today that it has received commitments topurchase US$10 million of units comprised of common shares and common sharepurchase warrants in a registered direct offering. AEterna Zentaris expects toreceive net proceeds of approximately US$9.25 million after deductingplacement agent fees and other offering expenses. Under the terms of aSecurities Purchase Agreement, the Company will sell to such institutionalinvestors an aggregate of 5,319,149 common shares of its capital at a price ofUS$1.88 per share and issue warrants to acquire an aggregate of 1,861,702common shares at an exercise price of US$2.06 per share.The warrants to purchase additional common shares of AEterna Zentaris will beexercisable beginning three months after issuance and will expire 30 monthsafter issuance. All of the common shares and warrants were offered pursuant toan effective shelf registration statement. Proceeds from the transaction willbe used for general corporate purposes, including clinical development of ourleading oncology and endocrinology compounds. The offering is expected to beconsummated no later than June 24, 2009, subject to customary closingconditions.Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc.,(Nasdaq: RODM ( )), acted as the exclusiveplacement agent for the transaction.

The placement agent will receivethirty-month warrants, exercisable beginning six months after issuance, topurchase 287,234 common shares at US$2.35 per share.In connection with the offering, the Company will file a prospectus supplementto its existing base shelf prospectus with the Canadian securities regulatoryauthorities and with the Securities and Exchange Commission. Copies of theprospectus supplement and accompanying prospectus may be obtained directlyfrom the Company or by contacting AEterna Zentaris Inc., 1405 duParc-Technologique Boulevard, Quebec City, Canada G1P 4P5.This press release shall not constitute an offer to sell or a solicitation ofan offer to buy any securities nor shall there be any sale of such securitiesin any jurisdiction in which such offer, solicitation or sale would beunlawful prior to registration or qualification under the securities laws ofany such jurisdiction. This offering is being made by means of a prospectussupplement to the Company’s existing base prospectus that is part of its shelfregistration statement previously filed with and declared effective by theSecurities and Exchange Commission.About AEterna Zentaris Inc.AEterna Zentaris Inc. is a global biopharmaceutical company focused onendocrine therapy and oncology, with proven expertise in drug discovery,development and commercialization.

News releases and additional informationare available at StatementsThis press release contains forward-looking statements made pursuant to thesafe harbor provisions of the U.S. Securities Litigation Reform Act of 1995.Forward-looking statements involve known and unknown risks and uncertainties,which could cause the Company’s actual results to differ materially from thosein the forward-looking statements. Such risks and uncertainties include, amongothers, the availability of funds and resources to pursue R&D projects, thesuccessful and timely completion of clinical studies, the ability of theCompany to take advantage of business opportunities in the pharmaceuticalindustry, uncertainties related to the regulatory process and general changesin economic conditions. Investors should consult the Company’s quarterly andannual filings with the Canadian and U.S. securities commissions foradditional information on risks and uncertainties relating to theforward-looking statements. Investors are cautioned not to rely on theseforward-looking statements. The Company does not undertake to update theseforward-looking statements.

LOS ANGELES (AFP) – La actriz y bailarina francesa Leslie Caron, que destacó en varias comedias musicales estadounidenses en la década de los 50, recibió el martes una estrella en el Paseo de la Fama de Hollywood.

The KR 16will be executing dry tool paths of the waterjet process around complex 3D partswith quick change tooling ability to demonstrate milling, drilling, and materialhandling. The quick tool changing function uses KUKA`s hand teach device,allowing for automatic tool change function and enabling the user to teach atool path manually using a joystick while utilizing KUKA safe robot technology.The KR16 robotic cell demonstration was designed and supplied by FlowInternational Corporation. In a robotic cell designed and supplied by Official KUKA Robotics SystemPartner, Dyco Inc. the flexible, fast handling KR5 Sixx will be demonstratedutilizing a vision system. The vision system enables the KR5 Sixx to locate andpick random plastic bottles from a moving conveyor belt simulating loading puckcarriers.

This same solution could be used for material handling to pick randombottles and load cases. KUKA Robotics will also display a KR5 Arc in a demo cell designed and suppliedby Electro-Hydraulic Automation an Official KUKA Robotics System Partner. Thedemo cell shows the highly versatile KR5 ARC holding an air powered cutting toolto trim and cut holes in plastics parts, simulating the cuts used in vehicledashboard openings. KUKA Robotics will display an injection molding extraction cell using the KR5Sixx. The KR5 Sixx features the flexibility of variable mounting options offloor or ceiling along with fast handling capabilities, will simulate theextraction of medical syringes from an injection molding machine.

BRUSELAS (AFP) – El actual primer ministro belga, Herman Van Rompuy, será el primer presidente de la Unión Europea (UE) y la británica Catherine Ashton, actual comisaria de Comercio, la ’superministra’ de Exteriores, acordaron los 27 líderes del bloque este jueves en la cumbre de Bruselas, informaron a la AFP fuentes diplomáticas.

The KR 16will be executing dry tool paths of the waterjet process around complex 3D partswith quick change tooling ability to demonstrate milling, drilling, and materialhandling. The quick tool changing function uses KUKA`s hand teach device,allowing for automatic tool change function and enabling the user to teach atool path manually using a joystick while utilizing KUKA safe robot technology.The KR16 robotic cell demonstration was designed and supplied by FlowInternational Corporation. In a robotic cell designed and supplied by Official KUKA Robotics SystemPartner, Dyco Inc. the flexible, fast handling KR5 Sixx will be demonstratedutilizing a vision system. The vision system enables the KR5 Sixx to locate andpick random plastic bottles from a moving conveyor belt simulating loading puckcarriers. This same solution could be used for material handling to pick randombottles and load cases. KUKA Robotics will also display a KR5 Arc in a demo cell designed and suppliedby Electro-Hydraulic Automation an Official KUKA Robotics System Partner.

Thedemo cell shows the highly versatile KR5 ARC holding an air powered cutting toolto trim and cut holes in plastics parts, simulating the cuts used in vehicledashboard openings. KUKA Robotics will display an injection molding extraction cell using the KR5Sixx. The KR5 Sixx features the flexibility of variable mounting options offloor or ceiling along with fast handling capabilities, will simulate theextraction of medical syringes from an injection molding machine. The KUKA Robotics System Partner network is designed to mutually benefit eachorganization`s users by extending the way customers can access tailoredsolutions from experienced system partners with the major competitive andtechnological advantage of high precision KUKA robots.

The KUKA Robotics SystemPartner Network includes experienced system builders, system providers,application specialists and expert robot integrators. KUKA robots are utilized in many different facets of the robotics industry fromautomotive, aerospace, consumer goods, logistics, food, pharmaceutical, medical,foundry and plastics industries and in multiple applications including materialhandling, packaging, palletizing, welding and surface finishing. For moreinformation contact KUKA Robotics at 866-873-5852 or visit their website at. About the KUKA Robot GroupKUKA Roboter GmbH, Augsburg, is a member of the KUKA Aktiengesellschaft andranks among the world`s leading suppliers of industrial robots.

Corecompetencies are the development, production and sale of industrial robots,controllers, software and linear units. The company is the market leader inGermany and Europe, and the number three in the world The KUKA Robot Groupemploys about 2,200 people worldwide. Of these, 1,200 are employed in Germany,either at the KUKA Robot Group headquarters in Augsburg, or at varioussubsidiaries In 2008, sales totaled 474 million euro. Twenty-six subsidiariesprovide a presence in the major markets of Europe, America and Asia.The KUKA logo is a registered trademark of KUKA Roboter GmbH KUKA, is atrademark of KUKA Roboter GmbH. All other trademarks are owned by theirrespective companies.KUKA Robotics CorporationMedia ContactRebecca MarkelMarketing ManagerPhone: Business Wire 2009. (Recasts on order against Google) Stocks  |  Media  |  China BEIJING, June 19 (Reuters) – China’s Internet watchdog onFriday ordered Google (GOOG.O) to stop overseas websites with”pornographic and vulgar” content from being accessed throughits Chinese-language search engine. The China Internet Illegal Information Reporting Centre hadtold Google to “make immediate changes” and clean up thecontent available through its search engine (),the official Xinhua news agency reported.

PUERTO PRÍNCIPE (AFP) – Cuando los gritos de las mujeres que dan a luz en el hospital general de Puerto Príncipe disminuyen, llantos más discretos comienzan a escucharse: son los bebés recién nacidos que escaparon del violento sismo que el 12 de enero golpeó a Haití.

(NASDAQ:AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrinetherapy and oncology, announced today that it has received commitments topurchase US$10 million of units comprised of common shares and common sharepurchase warrants in a registered direct offering. AEterna Zentaris expects toreceive net proceeds of approximately US$9.25 million after deductingplacement agent fees and other offering expenses. Under the terms of aSecurities Purchase Agreement, the Company will sell to such institutionalinvestors an aggregate of 5,319,149 common shares of its capital at a price ofUS$1.88 per share and issue warrants to acquire an aggregate of 1,861,702common shares at an exercise price of US$2.06 per share.The warrants to purchase additional common shares of AEterna Zentaris will beexercisable beginning three months after issuance and will expire 30 monthsafter issuance. All of the common shares and warrants were offered pursuant toan effective shelf registration statement. Proceeds from the transaction willbe used for general corporate purposes, including clinical development of ourleading oncology and endocrinology compounds.

The offering is expected to beconsummated no later than June 24, 2009, subject to customary closingconditions.Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc.,(Nasdaq: RODM ( )), acted as the exclusiveplacement agent for the transaction. The placement agent will receivethirty-month warrants, exercisable beginning six months after issuance, topurchase 287,234 common shares at US$2.35 per share.In connection with the offering, the Company will file a prospectus supplementto its existing base shelf prospectus with the Canadian securities regulatoryauthorities and with the Securities and Exchange Commission. Copies of theprospectus supplement and accompanying prospectus may be obtained directlyfrom the Company or by contacting AEterna Zentaris Inc., 1405 duParc-Technologique Boulevard, Quebec City, Canada G1P 4P5.This press release shall not constitute an offer to sell or a solicitation ofan offer to buy any securities nor shall there be any sale of such securitiesin any jurisdiction in which such offer, solicitation or sale would beunlawful prior to registration or qualification under the securities laws ofany such jurisdiction. This offering is being made by means of a prospectussupplement to the Company’s existing base prospectus that is part of its shelfregistration statement previously filed with and declared effective by theSecurities and Exchange Commission.About AEterna Zentaris Inc.AEterna Zentaris Inc. is a global biopharmaceutical company focused onendocrine therapy and oncology, with proven expertise in drug discovery,development and commercialization. News releases and additional informationare available at StatementsThis press release contains forward-looking statements made pursuant to thesafe harbor provisions of the U.S.

MADRID (AFP) – - El Ibex-35, índice de los principales valores de la Bolsa de Madrid, subió este miércoles 36,60 puntos (un 0,31%) y alcanzó las 11.853,30 unidades al final de la sesión.

The KR 16will be executing dry tool paths of the waterjet process around complex 3D partswith quick change tooling ability to demonstrate milling, drilling, and materialhandling. The quick tool changing function uses KUKA`s hand teach device,allowing for automatic tool change function and enabling the user to teach atool path manually using a joystick while utilizing KUKA safe robot technology.The KR16 robotic cell demonstration was designed and supplied by FlowInternational Corporation. In a robotic cell designed and supplied by Official KUKA Robotics SystemPartner, Dyco Inc. the flexible, fast handling KR5 Sixx will be demonstratedutilizing a vision system. The vision system enables the KR5 Sixx to locate andpick random plastic bottles from a moving conveyor belt simulating loading puckcarriers.

This same solution could be used for material handling to pick randombottles and load cases. KUKA Robotics will also display a KR5 Arc in a demo cell designed and suppliedby Electro-Hydraulic Automation an Official KUKA Robotics System Partner. Thedemo cell shows the highly versatile KR5 ARC holding an air powered cutting toolto trim and cut holes in plastics parts, simulating the cuts used in vehicledashboard openings. KUKA Robotics will display an injection molding extraction cell using the KR5Sixx. The KR5 Sixx features the flexibility of variable mounting options offloor or ceiling along with fast handling capabilities, will simulate theextraction of medical syringes from an injection molding machine. The KUKA Robotics System Partner network is designed to mutually benefit eachorganization`s users by extending the way customers can access tailoredsolutions from experienced system partners with the major competitive andtechnological advantage of high precision KUKA robots. The KUKA Robotics SystemPartner Network includes experienced system builders, system providers,application specialists and expert robot integrators.

ROMA (AFP) – El mediocampista inglés del AC Milan David Beckham, que salió del campo de juego lesionado de su pie izquierdo sobre el final del partido ante el Chievo Verona (1-0), este domingo en la 28ª jornada del ‘calcio’, sufrió la rotura del tendón de Aquiles, según Sky Sport TV.

The industrialend-user segment is also emerging as a significant source of retrofits, as plantowners have been investing in capacity expansions, new expansions, andrefurbishing aging power generation plants to improve productivity. Industrieshad invested substantially in brown field projects and maintenance and capacityreplacement in 2007, providing relief to gasket manufacturers. Although the economic slump is likely to defer a few industrial projects thatwere to be taken up in 2009 and 2010, the already initiated ones will go a longway in shoring up the gaskets market. The postponement of oil and gas expansionprojects will also curb the rapid growth of the market until 2010. “Decreasingoil prices are expected to reduce capacities until 2010, but with marketstabilization, the refurbishment of existing plants becomes necessary,” says theanalyst of this research. “The aftermarket business will see the gaskets marketsgrow moderately during this period.” Acknowledging the challenge of operating inthese difficult economic environments, companies all over the world are strivingto lower operational expenditure and improve returns on investment. With manycompanies also looking to considerably downsize maintenance personnel forequipment repair or breakdown, there is a large market for products that offerbetter reliability and life cycle cost benefits.

DUBLIN–(Business Wire)–Research and Markets( http://) hasannounced the addition of the “Three Case Studies in Technology Innovation(Apple, Google, Pixar)” report to their offering. This bundled report contains three innovation case studies, and focus on theinnovation efforts of Apple, Google, and Pixar. These three companies haveconsistently defined the cutting-edge in technology. In the Apple case study, learn how the company has re-emerged as one of theworld’s most innovative companies. Apple has managed to sustain its innovationefforts with calculated, consistent increases in R&D spending and rapid-firelaunches of new products and upgrades. Learn how Apple’s success has beenbecause the company has deliberately focused its efforts on generating betterideas faster.

In the Google case study, we take a look at their range of jaw-dropping productsand services that seem to literally tumble out of their innovation pipeline -Google Maps, Google Talk, and Google Page Creator to name just a few All ofthis innovation is backed by results. How do they manage to be so innovative -so consistently? Pixar is best known for its impressive track record of hit family movies,including: Toy Story 2, Finding Nemo, and The Incredibles. Pixar’s last sixmovies have grossed more than $3 billion in worldwide box office receipts, andPixar’s creative team members have won awards including Oscars, Gold Clios,Golden Globes and Grammys. What many filmgoers don’t know is that these greatartistic achievements were made possible by Pixar’s ability to create a climatethat fosters innovation. For more information visit http:// WoodSenior Fax from USA: 646-607-1907Fax from rest of the world: +353-1-481-1716 Copyright Business Wire 2009. DUBLIN–(Business Wire)–Research and Markets( http://) hasannounced the addition of the “Barr Pharmaceuticals Generics CompanyIntelligence Report” company profile to their offering.

- ‘Dentro de la tierra’ es el título de la obra del escritor andaluz Paco Bezerra que le ha llevado a ser galardonado como Premio Nacional de Literatura 2009 en la modalidad de Literatura Dramática, informó el Ministerio de Cultura este jueves a través de un comunicado.

The KR 16will be executing dry tool paths of the waterjet process around complex 3D partswith quick change tooling ability to demonstrate milling, drilling, and materialhandling. The quick tool changing function uses KUKA`s hand teach device,allowing for automatic tool change function and enabling the user to teach atool path manually using a joystick while utilizing KUKA safe robot technology.The KR16 robotic cell demonstration was designed and supplied by FlowInternational Corporation. In a robotic cell designed and supplied by Official KUKA Robotics SystemPartner, Dyco Inc. the flexible, fast handling KR5 Sixx will be demonstratedutilizing a vision system. The vision system enables the KR5 Sixx to locate andpick random plastic bottles from a moving conveyor belt simulating loading puckcarriers. This same solution could be used for material handling to pick randombottles and load cases.

KUKA Robotics will also display a KR5 Arc in a demo cell designed and suppliedby Electro-Hydraulic Automation an Official KUKA Robotics System Partner. Thedemo cell shows the highly versatile KR5 ARC holding an air powered cutting toolto trim and cut holes in plastics parts, simulating the cuts used in vehicledashboard openings. KUKA Robotics will display an injection molding extraction cell using the KR5Sixx. The KR5 Sixx features the flexibility of variable mounting options offloor or ceiling along with fast handling capabilities, will simulate theextraction of medical syringes from an injection molding machine. The KUKA Robotics System Partner network is designed to mutually benefit eachorganization`s users by extending the way customers can access tailoredsolutions from experienced system partners with the major competitive andtechnological advantage of high precision KUKA robots.

The KUKA Robotics SystemPartner Network includes experienced system builders, system providers,application specialists and expert robot integrators. KUKA robots are utilized in many different facets of the robotics industry fromautomotive, aerospace, consumer goods, logistics, food, pharmaceutical, medical,foundry and plastics industries and in multiple applications including materialhandling, packaging, palletizing, welding and surface finishing. For moreinformation contact KUKA Robotics at 866-873-5852 or visit their website at. About the KUKA Robot GroupKUKA Roboter GmbH, Augsburg, is a member of the KUKA Aktiengesellschaft andranks among the world`s leading suppliers of industrial robots. Corecompetencies are the development, production and sale of industrial robots,controllers, software and linear units. The company is the market leader inGermany and Europe, and the number three in the world The KUKA Robot Groupemploys about 2,200 people worldwide.

NUEVA YORK (AFP) – El fabricante de electrónica japonés Sony llamó este lunes a los propietarios de modelos antiguos de su consola de juegos PlayStation 3 a no usarlas, mientras repara una avería detectada el domingo en varios países.

The industrialend-user segment is also emerging as a significant source of retrofits, as plantowners have been investing in capacity expansions, new expansions, andrefurbishing aging power generation plants to improve productivity. Industrieshad invested substantially in brown field projects and maintenance and capacityreplacement in 2007, providing relief to gasket manufacturers. Although the economic slump is likely to defer a few industrial projects thatwere to be taken up in 2009 and 2010, the already initiated ones will go a longway in shoring up the gaskets market. The postponement of oil and gas expansionprojects will also curb the rapid growth of the market until 2010. “Decreasingoil prices are expected to reduce capacities until 2010, but with marketstabilization, the refurbishment of existing plants becomes necessary,” says theanalyst of this research.

“The aftermarket business will see the gaskets marketsgrow moderately during this period.” Acknowledging the challenge of operating inthese difficult economic environments, companies all over the world are strivingto lower operational expenditure and improve returns on investment. With manycompanies also looking to considerably downsize maintenance personnel forequipment repair or breakdown, there is a large market for products that offerbetter reliability and life cycle cost benefits. DUBLIN–(Business Wire)–Research and Markets( http://) hasannounced the addition of the “Three Case Studies in Technology Innovation(Apple, Google, Pixar)” report to their offering. This bundled report contains three innovation case studies, and focus on theinnovation efforts of Apple, Google, and Pixar. These three companies haveconsistently defined the cutting-edge in technology. In the Apple case study, learn how the company has re-emerged as one of theworld’s most innovative companies. Apple has managed to sustain its innovationefforts with calculated, consistent increases in R&D spending and rapid-firelaunches of new products and upgrades.

BELGRADO (AFP) – El seleccionador de Serbia de fútbol, Radomir Antic, renovó su contrato hasta 2012 tras haber clasificado al equipo nacional absoluto para el Mundial de Sudáfrica 2010, anunció este viernes la Federación del país europeo.

The KR 16will be executing dry tool paths of the waterjet process around complex 3D partswith quick change tooling ability to demonstrate milling, drilling, and materialhandling. The quick tool changing function uses KUKA`s hand teach device,allowing for automatic tool change function and enabling the user to teach atool path manually using a joystick while utilizing KUKA safe robot technology.The KR16 robotic cell demonstration was designed and supplied by FlowInternational Corporation. In a robotic cell designed and supplied by Official KUKA Robotics SystemPartner, Dyco Inc. the flexible, fast handling KR5 Sixx will be demonstratedutilizing a vision system. The vision system enables the KR5 Sixx to locate andpick random plastic bottles from a moving conveyor belt simulating loading puckcarriers. This same solution could be used for material handling to pick randombottles and load cases. KUKA Robotics will also display a KR5 Arc in a demo cell designed and suppliedby Electro-Hydraulic Automation an Official KUKA Robotics System Partner.

Thedemo cell shows the highly versatile KR5 ARC holding an air powered cutting toolto trim and cut holes in plastics parts, simulating the cuts used in vehicledashboard openings. KUKA Robotics will display an injection molding extraction cell using the KR5Sixx. The KR5 Sixx features the flexibility of variable mounting options offloor or ceiling along with fast handling capabilities, will simulate theextraction of medical syringes from an injection molding machine. The KUKA Robotics System Partner network is designed to mutually benefit eachorganization`s users by extending the way customers can access tailoredsolutions from experienced system partners with the major competitive andtechnological advantage of high precision KUKA robots. The KUKA Robotics SystemPartner Network includes experienced system builders, system providers,application specialists and expert robot integrators. KUKA robots are utilized in many different facets of the robotics industry fromautomotive, aerospace, consumer goods, logistics, food, pharmaceutical, medical,foundry and plastics industries and in multiple applications including materialhandling, packaging, palletizing, welding and surface finishing. For moreinformation contact KUKA Robotics at 866-873-5852 or visit their website at.

NUEVA YORK (AFP) – - El presidente de Estados Unidos, Barack Obama, clamó por una nueva era de cooperación multilateral al descartar que Estados Unidos pueda resolver todos los problemas del mundo en su debut este miércoles ante la Asamblea General de la ONU.

The KR 16will be executing dry tool paths of the waterjet process around complex 3D partswith quick change tooling ability to demonstrate milling, drilling, and materialhandling. The quick tool changing function uses KUKA`s hand teach device,allowing for automatic tool change function and enabling the user to teach atool path manually using a joystick while utilizing KUKA safe robot technology.The KR16 robotic cell demonstration was designed and supplied by FlowInternational Corporation. In a robotic cell designed and supplied by Official KUKA Robotics SystemPartner, Dyco Inc. the flexible, fast handling KR5 Sixx will be demonstratedutilizing a vision system.

The vision system enables the KR5 Sixx to locate andpick random plastic bottles from a moving conveyor belt simulating loading puckcarriers. This same solution could be used for material handling to pick randombottles and load cases. KUKA Robotics will also display a KR5 Arc in a demo cell designed and suppliedby Electro-Hydraulic Automation an Official KUKA Robotics System Partner. Thedemo cell shows the highly versatile KR5 ARC holding an air powered cutting toolto trim and cut holes in plastics parts, simulating the cuts used in vehicledashboard openings.

KUKA Robotics will display an injection molding extraction cell using the KR5Sixx. The KR5 Sixx features the flexibility of variable mounting options offloor or ceiling along with fast handling capabilities, will simulate theextraction of medical syringes from an injection molding machine. The KUKA Robotics System Partner network is designed to mutually benefit eachorganization`s users by extending the way customers can access tailoredsolutions from experienced system partners with the major competitive andtechnological advantage of high precision KUKA robots. The KUKA Robotics SystemPartner Network includes experienced system builders, system providers,application specialists and expert robot integrators. KUKA robots are utilized in many different facets of the robotics industry fromautomotive, aerospace, consumer goods, logistics, food, pharmaceutical, medical,foundry and plastics industries and in multiple applications including materialhandling, packaging, palletizing, welding and surface finishing. For moreinformation contact KUKA Robotics at 866-873-5852 or visit their website at.

About the KUKA Robot GroupKUKA Roboter GmbH, Augsburg, is a member of the KUKA Aktiengesellschaft andranks among the world`s leading suppliers of industrial robots. Corecompetencies are the development, production and sale of industrial robots,controllers, software and linear units. The company is the market leader inGermany and Europe, and the number three in the world The KUKA Robot Groupemploys about 2,200 people worldwide. Of these, 1,200 are employed in Germany,either at the KUKA Robot Group headquarters in Augsburg, or at varioussubsidiaries In 2008, sales totaled 474 million euro. Twenty-six subsidiariesprovide a presence in the major markets of Europe, America and Asia.The KUKA logo is a registered trademark of KUKA Roboter GmbH KUKA, is atrademark of KUKA Roboter GmbH.

SANTIAGO DE COMPOSTELA (AFP) – La ciudad de Santiago de Compostela, meta del célebre Camino de Santiago, acoge este jueves los actos que dan comienzo a la apertura del Año Santo Compostelano, durante el cual la Iglesia católica concede la indulgencia plenaria a quienes acuden hasta allí.

(NASDAQ:AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrinetherapy and oncology, announced today that it has received commitments topurchase US$10 million of units comprised of common shares and common sharepurchase warrants in a registered direct offering. AEterna Zentaris expects toreceive net proceeds of approximately US$9.25 million after deductingplacement agent fees and other offering expenses. Under the terms of aSecurities Purchase Agreement, the Company will sell to such institutionalinvestors an aggregate of 5,319,149 common shares of its capital at a price ofUS$1.88 per share and issue warrants to acquire an aggregate of 1,861,702common shares at an exercise price of US$2.06 per share.The warrants to purchase additional common shares of AEterna Zentaris will beexercisable beginning three months after issuance and will expire 30 monthsafter issuance. All of the common shares and warrants were offered pursuant toan effective shelf registration statement. Proceeds from the transaction willbe used for general corporate purposes, including clinical development of ourleading oncology and endocrinology compounds. The offering is expected to beconsummated no later than June 24, 2009, subject to customary closingconditions.Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc.,(Nasdaq: RODM ( )), acted as the exclusiveplacement agent for the transaction.

The placement agent will receivethirty-month warrants, exercisable beginning six months after issuance, topurchase 287,234 common shares at US$2.35 per share.In connection with the offering, the Company will file a prospectus supplementto its existing base shelf prospectus with the Canadian securities regulatoryauthorities and with the Securities and Exchange Commission. Copies of theprospectus supplement and accompanying prospectus may be obtained directlyfrom the Company or by contacting AEterna Zentaris Inc., 1405 duParc-Technologique Boulevard, Quebec City, Canada G1P 4P5.This press release shall not constitute an offer to sell or a solicitation ofan offer to buy any securities nor shall there be any sale of such securitiesin any jurisdiction in which such offer, solicitation or sale would beunlawful prior to registration or qualification under the securities laws ofany such jurisdiction. This offering is being made by means of a prospectussupplement to the Company’s existing base prospectus that is part of its shelfregistration statement previously filed with and declared effective by theSecurities and Exchange Commission.About AEterna Zentaris Inc.AEterna Zentaris Inc. is a global biopharmaceutical company focused onendocrine therapy and oncology, with proven expertise in drug discovery,development and commercialization.

News releases and additional informationare available at StatementsThis press release contains forward-looking statements made pursuant to thesafe harbor provisions of the U.S. Securities Litigation Reform Act of 1995.Forward-looking statements involve known and unknown risks and uncertainties,which could cause the Company’s actual results to differ materially from thosein the forward-looking statements. Such risks and uncertainties include, amongothers, the availability of funds and resources to pursue R&D projects, thesuccessful and timely completion of clinical studies, the ability of theCompany to take advantage of business opportunities in the pharmaceuticalindustry, uncertainties related to the regulatory process and general changesin economic conditions. Investors should consult the Company’s quarterly andannual filings with the Canadian and U.S. securities commissions foradditional information on risks and uncertainties relating to theforward-looking statements. Investors are cautioned not to rely on theseforward-looking statements. The Company does not undertake to update theseforward-looking statements.

We disclaim any obligation to update any suchfactors or to publicly announce the result of any revisions to any of theforward-looking statements contained herein to reflect future results, eventsor developments except if we are requested by a governmental authority orapplicable law.SOURCEAETERNA ZENTARIS INC.Investor Relations: Ginette Vallieres, Investor Relations Coordinator, (418)652-8525 ext. 265, ; Media Relations: Paul Burroughs,Director of Communications, (418) 652-8525 ext. 406, . FREDERICK, MD, Jun 19 (MARKET WIRE) — BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive,disposable drug-free anti-inflammatory devices, today provided itsinvestors with a summary of the conference call held after the marketclosed on Thursday, June 18th. On the conference call, the managementteam discussed the numerous ongoing clinical trials, expected FDAsubmissions and the Company’s marketing plans through the end of theyear.

MADRID (AFP) – Real Madrid derrotó 5-1 al Tenerife, este sábado en la 24ª jornada de la Liga española de fútbol, con un ‘doblete’ inicial del argentino Gonzalo Higuaín (29, 42), y trasladó la presión al Barcelona, que juega como local con el Málaga (21h00 GMT).

The industrialend-user segment is also emerging as a significant source of retrofits, as plantowners have been investing in capacity expansions, new expansions, andrefurbishing aging power generation plants to improve productivity. Industrieshad invested substantially in brown field projects and maintenance and capacityreplacement in 2007, providing relief to gasket manufacturers. Although the economic slump is likely to defer a few industrial projects thatwere to be taken up in 2009 and 2010, the already initiated ones will go a longway in shoring up the gaskets market. The postponement of oil and gas expansionprojects will also curb the rapid growth of the market until 2010. “Decreasingoil prices are expected to reduce capacities until 2010, but with marketstabilization, the refurbishment of existing plants becomes necessary,” says theanalyst of this research.

“The aftermarket business will see the gaskets marketsgrow moderately during this period.” Acknowledging the challenge of operating inthese difficult economic environments, companies all over the world are strivingto lower operational expenditure and improve returns on investment. With manycompanies also looking to considerably downsize maintenance personnel forequipment repair or breakdown, there is a large market for products that offerbetter reliability and life cycle cost benefits. DUBLIN–(Business Wire)–Research and Markets( http://) hasannounced the addition of the “Three Case Studies in Technology Innovation(Apple, Google, Pixar)” report to their offering. This bundled report contains three innovation case studies, and focus on theinnovation efforts of Apple, Google, and Pixar. These three companies haveconsistently defined the cutting-edge in technology. In the Apple case study, learn how the company has re-emerged as one of theworld’s most innovative companies.

DETROIT, EEUU (AFP) – El fallido atentado de un joven nigeriano a bordo de un avión estadounidense que cubría la ruta entre Amsterdam y Detroit desató una vasta investigación internacional este sábado y obligó a los principales aeropuertos del mundo a reforzar su seguridad.

(NASDAQ:AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrinetherapy and oncology, announced today that it has received commitments topurchase US$10 million of units comprised of common shares and common sharepurchase warrants in a registered direct offering. AEterna Zentaris expects toreceive net proceeds of approximately US$9.25 million after deductingplacement agent fees and other offering expenses. Under the terms of aSecurities Purchase Agreement, the Company will sell to such institutionalinvestors an aggregate of 5,319,149 common shares of its capital at a price ofUS$1.88 per share and issue warrants to acquire an aggregate of 1,861,702common shares at an exercise price of US$2.06 per share.The warrants to purchase additional common shares of AEterna Zentaris will beexercisable beginning three months after issuance and will expire 30 monthsafter issuance. All of the common shares and warrants were offered pursuant toan effective shelf registration statement.

Proceeds from the transaction willbe used for general corporate purposes, including clinical development of ourleading oncology and endocrinology compounds. The offering is expected to beconsummated no later than June 24, 2009, subject to customary closingconditions.Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc.,(Nasdaq: RODM ( )), acted as the exclusiveplacement agent for the transaction. The placement agent will receivethirty-month warrants, exercisable beginning six months after issuance, topurchase 287,234 common shares at US$2.35 per share.In connection with the offering, the Company will file a prospectus supplementto its existing base shelf prospectus with the Canadian securities regulatoryauthorities and with the Securities and Exchange Commission. Copies of theprospectus supplement and accompanying prospectus may be obtained directlyfrom the Company or by contacting AEterna Zentaris Inc., 1405 duParc-Technologique Boulevard, Quebec City, Canada G1P 4P5.This press release shall not constitute an offer to sell or a solicitation ofan offer to buy any securities nor shall there be any sale of such securitiesin any jurisdiction in which such offer, solicitation or sale would beunlawful prior to registration or qualification under the securities laws ofany such jurisdiction. This offering is being made by means of a prospectussupplement to the Company’s existing base prospectus that is part of its shelfregistration statement previously filed with and declared effective by theSecurities and Exchange Commission.About AEterna Zentaris Inc.AEterna Zentaris Inc. is a global biopharmaceutical company focused onendocrine therapy and oncology, with proven expertise in drug discovery,development and commercialization.

News releases and additional informationare available at StatementsThis press release contains forward-looking statements made pursuant to thesafe harbor provisions of the U.S. Securities Litigation Reform Act of 1995.Forward-looking statements involve known and unknown risks and uncertainties,which could cause the Company’s actual results to differ materially from thosein the forward-looking statements. Such risks and uncertainties include, amongothers, the availability of funds and resources to pursue R&D projects, thesuccessful and timely completion of clinical studies, the ability of theCompany to take advantage of business opportunities in the pharmaceuticalindustry, uncertainties related to the regulatory process and general changesin economic conditions. Investors should consult the Company’s quarterly andannual filings with the Canadian and U.S. securities commissions foradditional information on risks and uncertainties relating to theforward-looking statements.

MIAMI (AFP) – Junto a una de las autopistas que se adentra en Miami Beach, un llamativo campamento de una decena de carpas reúne a una comunidad de abusadores sexuales que, rechazados de los albergues para personas sin techo, resisten allí como pueden el frío polar en el sureste estadounidense.

(NASDAQ:AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrinetherapy and oncology, announced today that it has received commitments topurchase US$10 million of units comprised of common shares and common sharepurchase warrants in a registered direct offering. AEterna Zentaris expects toreceive net proceeds of approximately US$9.25 million after deductingplacement agent fees and other offering expenses. Under the terms of aSecurities Purchase Agreement, the Company will sell to such institutionalinvestors an aggregate of 5,319,149 common shares of its capital at a price ofUS$1.88 per share and issue warrants to acquire an aggregate of 1,861,702common shares at an exercise price of US$2.06 per share.The warrants to purchase additional common shares of AEterna Zentaris will beexercisable beginning three months after issuance and will expire 30 monthsafter issuance. All of the common shares and warrants were offered pursuant toan effective shelf registration statement. Proceeds from the transaction willbe used for general corporate purposes, including clinical development of ourleading oncology and endocrinology compounds. The offering is expected to beconsummated no later than June 24, 2009, subject to customary closingconditions.Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc.,(Nasdaq: RODM ( )), acted as the exclusiveplacement agent for the transaction. The placement agent will receivethirty-month warrants, exercisable beginning six months after issuance, topurchase 287,234 common shares at US$2.35 per share.In connection with the offering, the Company will file a prospectus supplementto its existing base shelf prospectus with the Canadian securities regulatoryauthorities and with the Securities and Exchange Commission.

Copies of theprospectus supplement and accompanying prospectus may be obtained directlyfrom the Company or by contacting AEterna Zentaris Inc., 1405 duParc-Technologique Boulevard, Quebec City, Canada G1P 4P5.This press release shall not constitute an offer to sell or a solicitation ofan offer to buy any securities nor shall there be any sale of such securitiesin any jurisdiction in which such offer, solicitation or sale would beunlawful prior to registration or qualification under the securities laws ofany such jurisdiction. This offering is being made by means of a prospectussupplement to the Company’s existing base prospectus that is part of its shelfregistration statement previously filed with and declared effective by theSecurities and Exchange Commission.About AEterna Zentaris Inc.AEterna Zentaris Inc. is a global biopharmaceutical company focused onendocrine therapy and oncology, with proven expertise in drug discovery,development and commercialization. News releases and additional informationare available at StatementsThis press release contains forward-looking statements made pursuant to thesafe harbor provisions of the U.S. Securities Litigation Reform Act of 1995.Forward-looking statements involve known and unknown risks and uncertainties,which could cause the Company’s actual results to differ materially from thosein the forward-looking statements. Such risks and uncertainties include, amongothers, the availability of funds and resources to pursue R&D projects, thesuccessful and timely completion of clinical studies, the ability of theCompany to take advantage of business opportunities in the pharmaceuticalindustry, uncertainties related to the regulatory process and general changesin economic conditions. Investors should consult the Company’s quarterly andannual filings with the Canadian and U.S.

securities commissions foradditional information on risks and uncertainties relating to theforward-looking statements. Investors are cautioned not to rely on theseforward-looking statements. The Company does not undertake to update theseforward-looking statements. We disclaim any obligation to update any suchfactors or to publicly announce the result of any revisions to any of theforward-looking statements contained herein to reflect future results, eventsor developments except if we are requested by a governmental authority orapplicable law.SOURCEAETERNA ZENTARIS INC.Investor Relations: Ginette Vallieres, Investor Relations Coordinator, (418)652-8525 ext.